Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone with Standard Therapy for Hepatitis C Genotype 1 with Steatosis
NCT00274495Phase 4Terminated
- Sponsor
- Mount Sinai Beth Israel
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rosiglitazone in hepatitis C (HCV), fatty liver disease (FLD), sponsored by Mount Sinai Beth Israel. Started Jan 2006; status: terminated.
02
Drugs
rosiglitazone
03
Conditions
hepatitis C (HCV)fatty liver disease (FLD)
Beyond the preview
Go deeper on NCT00274495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00274495.